Trial · NCT00114972

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries

NCT00114972, Phase 3, Unknown, Boston Scientific Corporation; results first posted 2010-06-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries. Trials, record NCT00114972. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00114972

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries
NCT number: NCT00114972
Status: Unknown
Phases: Phase 3
Enrollment: 1,800 participants, actual
Lead sponsor: Boston Scientific Corporation
Conditions: Coronary Artery Disease
Interventions: Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent, Coronary Artery Bypass Surgery
First posted: 2005-06-21
Last updated: 2010-06-23
Results first posted: 2010-06-23

Source ClinicalTrials.gov

Registered outcomes13

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Primary Clinical Endpoint of 12-Month Binary MACCE.	12 months post enrollment	Number of participants at primary clinical endpoint of 12-Month binary MACCE. MACCE is defined as: all cause death, cerebrovascular event (stroke), cocumented myocardial infarction, repeat revascularization (PCI and/or CABG).
Primary	12-month Composite Safety Endpoint.	12 months after enrollment	Number of participants at 12-month composite safety endpoint. Composite safety endpoint combines: all cause death, cerebrovascular event (stroke), and documented myocardial infarction.
Primary	Repeat Revascularization (PCI and/or CABG).	12 Months post enrollment	Number of participants with repeat revascularization (PCI and/or CABG).
Secondary	Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.	1 month after procedure and 6 months, 3 years, and 5 years post allocation	Number of participants with Overall MACCE at 1 month post-procedure and at 6 months, 3 years, and 5 years post-allocation.
Secondary	Individual Components of MACCE at 1 Month Post-procedure.	1 month after procedure	Number of participants with individual components of MACCE at 1 month post-procedure. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.
Secondary	Individual Components of MACCE at 6 Months Post-allocation.	6 months post allocation	Number of participants with individual components of MACCE at 6 months post-allocation. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.
Secondary	Individual Components of MACCE at 1 Year Post-allocation.	1 year post allocation	Number of participants with individual components of MACCE at 1 year post-allocation. The individual components of MACCE are: all cause death, stroke, documented myocardial infarction, repeat revascularization.
Secondary	Freedom From MACCE and Its Components at 1 Year Post-allocation.	1 year post allocation	Number of participants with freedom from MACCE and its components at 1 year post-allocation. Freedom from MACCE is defined as no MACCE nor any of the individual components of MACCE (all cause death, stroke, documented myocardial infarction, repeat revascularization).
Secondary	Freedom From MACCE and Its Components at 3 Years Post-allocation	3 years post allocation
Secondary	Freedom From MACCE and Its Components at 5 Years Post-allocation	5 years post allocation

1 to 10 of 13Source ClinicalTrials.gov

See all 13 registered outcomes

Outcomes13

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Primary Clinical Endpoint of 12-Month Binary MACCE.	12 months post enrollment	ITT analysis. Number of participants analyzed equals number of subjects who completed Overall Study, as listed in Participant Flow.	participants	NUMBER
PRIMARY	12-month Composite Safety Endpoint.	12 months after enrollment		participants	NUMBER
SECONDARY	Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.	1 month after procedure and 6 months, 3 years, and 5 years post allocation		participants	NUMBER
SECONDARY	Individual Components of MACCE at 1 Month Post-procedure.	1 month after procedure	ITT analysis	participants	NUMBER
SECONDARY	Individual Components of MACCE at 6 Months Post-allocation.	6 months post allocation	ITT analysis	Participants	NUMBER
SECONDARY	Individual Components of MACCE at 1 Year Post-allocation.	1 year post allocation	ITT analysis	participants	NUMBER
SECONDARY	Freedom From MACCE and Its Components at 1 Year Post-allocation.	1 year post allocation		participants	NUMBER
SECONDARY	Freedom From MACCE and Its Components at 3 Years Post-allocation	3 years post allocation		participants	NUMBER
PRIMARY	Repeat Revascularization (PCI and/or CABG).	12 Months post enrollment		Participants	NUMBER
SECONDARY	Freedom From MACCE and Its Components at 5 Years Post-allocation	5 years post allocation		participants	NUMBER

1 to 10 of 13Source ClinicalTrials.gov

See all 13 outcomes

Results by group44

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Units
Primary Clinical Endpoint of 12-Month Binary MACCE.	CABG		105	participants
Primary Clinical Endpoint of 12-Month Binary MACCE.	PCI With DES		159	participants
12-month Composite Safety Endpoint.	CABG		65	participants
12-month Composite Safety Endpoint.	PCI With DES		68	participants
Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.	CABG	MACCE 1 month post procedure	45	participants
Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.	PCI With DES	MACCE 1 month post procedure	54	participants
Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.	CABG	MACCE 6 months post procedure	85	participants
Overall MACCE at 1 Month Post-procedure and at 6 Months, 3 Years, and 5 Years Post-allocation.	PCI With DES	MACCE 6 months post procedure	111	participants
Individual Components of MACCE at 1 Month Post-procedure.	CABG	All cause death	10	participants
Individual Components of MACCE at 1 Month Post-procedure.	PCI With DES	All cause death	20	participants

1 to 10 of 44Source ClinicalTrials.gov

See all 44 results by group

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	CABG	897
Overall Study	STARTED	PCI With DES	903
Overall Study	COMPLETED	CABG	849
Overall Study	COMPLETED	PCI With DES	891
Overall Study	NOT COMPLETED	CABG	48
Overall Study	NOT COMPLETED	PCI With DES	12

Source ClinicalTrials.gov

Adverse events118

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	CABG	104	897	109
other	Anaemia	Blood and lymphatic system disorders	PCI With DES	23	903	24
other	Angina pectoris	Cardiac disorders	CABG	26	897	28
other	Angina pectoris	Cardiac disorders	PCI With DES	61	903	70
other	Atrial fibrillation	Cardiac disorders	CABG	123	897	129
other	Atrial fibrillation	Cardiac disorders	PCI With DES	25	903	28
other	Incision site complication	Injury, poisoning and procedural complications	CABG	47	897	52
other	Incision site complication	Injury, poisoning and procedural complications	PCI With DES	3	903	3
other	Pleural effusion	Respiratory, thoracic and mediastinal disorders	CABG	54	897	55
other	Pleural effusion	Respiratory, thoracic and mediastinal disorders	PCI With DES	2	903	2

1 to 10 of 118Source ClinicalTrials.gov

See all 118 adverse events

Adverse event totals6

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	CABG
Total, all-cause mortality	PCI With DES
Total, other adverse events	CABG	509	897
Total, other adverse events	PCI With DES	405	903
Total, serious adverse events	CABG	391	897
Total, serious adverse events	PCI With DES	357	903

Source ClinicalTrials.gov

Papers58

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
19228612	DERIVED	PubMed
20079596	DERIVED	PubMed
20530001	DERIVED	PubMed
21168023	DERIVED	PubMed
21410370	DERIVED	PubMed
21959312	DERIVED	PubMed
22496114	DERIVED	PubMed
22721655	DERIVED	PubMed
22721656	DERIVED	PubMed
23439102	DERIVED	PubMed

1 to 10 of 58

See all 58 papers

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons4

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

Comparison	Source
CABG vs PCI With DES: Repeat Revascularization (PCI and/or CABG).	Trial comparisons
CABG vs PCI With DES: Primary Clinical Endpoint of 12-Month Binary MACCE.	Trial comparisons
CABG vs PCI With DES: 12-month Composite Safety Endpoint.	Trial comparisons
CABG vs PCI With DES: serious adverse events	Trial comparisons

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00114972

GET https://conductscience.org/api/trials/v1/NCT00114972/results?page=2

API reference For AI assistants